Nextgen Share Discussion Threads

[the_doctor] 22/6/2011 15:29

I'm not out to convince anyone to sell, just to encourage people to think rather than be suckered in by some of the more lofty valuation targets that I disagree with - particularly from those that have no basis for their calls other than an intent to ramp. My reason for posting was also actually primarily to hear what people expected from NGG and why, since I follow other co.s in the segment.

[nmj2] 22/6/2011 14:48

the doctor , you,ve convinced me they,re not worth it so i,m selling my holding over the next three working days in peices so as not to scare off the long termers ,last post goodbye.

[the_doctor] 22/6/2011 11:48

NMJ2, what I suggested was naive were your comments in 257 that have nothing to do with whether NGG will make money

You've still not explained why NGG's assays will make much.


'but for the life of me i can,t see why your here'

I'm here to pass on learnings from other company's assays to suggest that people think carefully about how much the assays will earn.
Not you, but there are some vicious rampers that jumped on the 'biospike' bandwagon.

[nmj2] 21/6/2011 21:54

the doctor nextgen have and continue to re-iterete they are bringing new assays to the market place all the time their area of technology may not be as broad as others but they outweigh this by far with lower overheads even to the constant reveiwing of senior staff wage structures to ensure when the contracts come they will be financially capable of supplying a product that will meet the demands ahead , i may have a naive veiw of their prospects in your opinion but that really means nothing to me , i have nothing to prove to anyone i did all that when i was in my twenties and thirties ,my financial future is and has allways been secure but for the life of me i can,t see why your here if everyone else is so much better than nextgen , to me small companies like this and many others i unashamedly have made money from are the thing that gets our blood flowing one minute the markets hate them , the next they love em sell at the top of the spike , buy back when they,re low it,s all good , without these the whole trading scene would be tedious and mind knumbingly boring we can all look up a few facts to make ourselves feel important on a bulletin board but at the end of the day we all know who we really are .

[the_doctor] 21/6/2011 17:58

bit of a naive view, no?

It all depends on what markers are covered and what volume use there'll be.

My investment in PRM for example, is not about the research assays, but about
- licenses for its proprietary biomarkers
- the expansion of TMT-based MS asays (needed for high accuracy of some lowere conc proteins, but TMT also now branching into other marker types too)
- licences for TMT commercial use
- contracts to have work done involving its proprietary (and other) protein assays
- deals for therapeutic AD rights

NextGen is focused on the one area of PRM that I'm least excited about
as such, I'm intrigued to hear what you expect will drive the business.

All said though, I could still see it commanding sizeable contracts.
Ideally they'll both be a success :o)

I actually think the coming new PRM website will be in a step towards something like NGG's

[nmj2] 21/6/2011 17:28

the doctor ,do you think the biomarkers for the people suffering from these conditions is not a significant step forward then ,any company attempting to find a way to alleviate suffering through technological advances should be given a break otherwise we would all be living in the dark ages and dieing at the age of 30

[the_doctor] 21/6/2011 17:17

doesnt answer the question
RBM had 500 assays, but made only about £1m per year

I reiterate that IMO, what companies in this space need are
- key biomarkers to command large deals
- sufficiently attractive technology to get high volume use
- therapeutic IP

[nmj2] 21/6/2011 17:16

The doctor , i have a few shareholdings in companies involved in neurological and oncology assays including GPCRS,ion channels ,proteases and kinases as well as other enzymes such as transmembrane ,proteins and adhesion molecules ,the companies involved can generate assays to different formats including

labelling chemistry

calcium dyes and voltage sensitive dyes

cell viability assays(mts)

and flourescent based cellular assays

[the_doctor] 21/6/2011 16:41

NMJ2, I'm not sure you quite understand the assays position, but good luck.
Maybe they'll get that 'golden' contract.
I suspect you may be disappointed.

IMO, what companies in this space need are
- key biomarkers to command large deals
- sufficiently attractive technology to get high volume use
- therapeutic IP

[nmj2] 21/6/2011 16:35

the doctor, the assay launch is significant because its another product that offers a money return and also helps in procuring that golden company changing contract , used to have prm myself no more made money moved on , nextgen is a keeper they have a specific product in biomarker assays with little competition just need more recognition of the complexity required to bring these to the markets and less interferance from the markets , virtually everybody i know involved in trading doesn,t hold stocks and bonds for the company or what it stands for , they are there to make money , being interested in what they sell is just that interest , i have held shares and options for over 15 years in some companies because they have come out the other side a healthy profit ( bt bought for £2.25 sold at £21.11) back in the nineties ,nextgen is a nice little well organised company with a great deal of promise i should know i have two companies of my own plus a large portfolio of share holdings spread across 3 continents the day will come when these are the new sareum ngg needs positive support and less of the short term criticism aimed at it over the past year ,the biomarker assay market in this country is still growing and they will be amongst the leaders.

[the_doctor] 21/6/2011 15:17

'crikey whats nextgen gotta do give every shareholder a free porsche'

NMJ2, I'd say you're missing that the assay launch isnt so significant. It's getting it used that counts.

I hold PRM and have seen the challenges, although the two companies are different

[ukmassy] 21/6/2011 15:05

MM's taking the mickey again. Buys going through as sells. Ridiculous spread.

[lady gaga] 21/6/2011 07:47

.5p anyone lol









Home

Log In

Register

Our Services

My Account

Contact

Help




Stockwatch

Level 2

Portfolio

Charts

Shares Magazine

Research

Share Price

Indices

Market Scan

Company Zone

Traders' Room



NewsWatch

Trades

Terminal

Alerts

Stock Screener

Heatmaps

News

iPhone

Forex

Director Deals

Investors' Room



Credit Cards

A-Z of Brokers

Directory

Bookshop

Awards 2011

Mortgages

ISAs

PLUS

Simply Chart

Broker Notes

Forward Diary


You are NOT currently logged in

.










Keyword
Company
EPIC/TIDM
SEDOL/ISIN







Print


Tuesday 21 June, 2011


NextGen Group PLC

New Assay Launch


RNS Number : 7769I

NextGen Group PLC

21 June 2011






NextGen Group Plc



NextGen Sciences launches multiple protein cerebrospinal fluid (CSF) CNS disease biomarker assay



London, UK and Ann Arbor, Michigan, US, 21 June 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first cerebrospinal fluid (CSF) multiple protein (multiplex) assay, csfdiscovery43, for central nervous system (CNS) biomarker discovery and qualification. The assay simultaneously measures 43 human CSF proteins that are thought to have potential as biomarkers in CNS diseases, particularly Alzheimer's, Parkinson's, multiple sclerosis and ALS diseases. The launch of csfdiscovery43 is the next step in NextGen Sciences strategy of becoming a leading player in the growing CNS and oncology biomarker markets.



NextGen's assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform, and generates high quality reproducible data that companies can use in their drug and diagnostic development programmes. In addition to the CNS disease focus, the assay can be used for early-stage biomarker discovery and qualification in other disease areas e.g. traumatic brain injury (TBI). NextGen expects to continue to add proteins to the csfdiscovery43 assay, in addition to developing other disease-focused assay panels, both as proprietary products and with other companies through partnerships and collaborations.



Klaus Rosenau, Chairman and CEO of NextGen Group, commented, 'The release of csfdiscovery43 is the next defining step in the development of NextGen Sciences' biomarker business, following its reorganization and release of the plasmadiscovery41 assay in Q1. It demonstrates that we have once again delivered on our plans to develop multiplex protein assays that will help to establish the company as a market leader in biomarker discovery and qualification using its MRM technology. Importantly, this enables us to further target increasing market share from the $600m mass spectrometry based biomarker discovery market. We believe that pharmaceutical, biotechnology and diagnostics companies need high-quality assays relevant to their disease areas to inform their decision-making processes, and NextGen Sciences is currently working on the launch of more such products.'



- ENDS -



For more information please contact :



NextGen Group

Klaus Rosenau, Chairman and CEO

[e-mail]

[phone]



Seymour Pierce

Jonathan Wright, Nicola Marrin

[phone]







Notes to Editors



NextGen Sciences Inc (Ann Arbor, MI, USA) is the subsidiary of NextGen Group PLC, London, UK (AIM: NGG). It provides pharmaceutical, biotechnology and diagnostic companies with rapid and quantitative protein biomarker discovery, measurement and qualification services using mass spectrometry technology. With a rise in the industry focus on personalized medicine and cost-effectiveness, biomarkers are playing an increasing important role in drug discovery, development and patient access, as well as healthcare delivery. The global market for biomarkers is expected to grow to $12.8bn by 2012 (BCC Research), with those for neurological disorders ($3.5bn by 2015, Espicom Healthcare) and oncology ($9.5bn by 2014, www.marketsandmarkets.com) playing an important role. NextGen Sciences' products include discovery assays, oncology assays, CNS assays and cardiovascular assays for biomarker discovery and qualification. For more information please visit www.nextgensciences.com.














This information is provided by RNS

The company news service from the London Stock Exchange


END



MSCSESFMSFFSEFM



Investegate takes no responsibility for the accuracy of the information within the site.


The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site.

--------------------------------------------------------------------------------


© 2011 Financial Express. All rights reserved.















Stockwatch

Level 2

Portfolio

Charts

Shares Magazine

Research

Share Price

Indices

Market Scan

Company Zone

Traders' Room



NewsWatch

Trades

Terminal

Alerts

Stock Screener

Heatmaps

News

iPhone

Forex

Director Deals

Investors' Room



Credit Cards

A-Z of Brokers

Directory

Bookshop

Awards 2011

Mortgages

ISAs

PLUS

Simply Chart

Broker Notes

Forward Diary




About an ADVFN competitor

Ts and Cs

Privacy Policy

Investment Warning

Content Standards

Corporate Solutions

Advertise With Us

Site Map

© 2011 an ADVFN competitor


Register now for FREE Share Prices, Stock Quotes, Charts, Bulletin Boards, Indices, Watchlists, Portfolio, Market News, Research or see our Premium Services including Level 2, Terminal and much more.
Follow us on Twitter

[bobby.ifa] 12/6/2011 23:30

Well, I wish they'd hurry up, I have too many of these in my SIPP, current retirement now stands at 79.

[lady gaga] 12/6/2011 21:49

Were of the same thinking.

Just one contract and this is life changing.

[nmj2] 08/6/2011 11:51

i,ve held 6.25 mil shares in these now for 3 years averaged out at .17 p and can never understand the total lack of interest in what is a company on the rise with products well worth investing in with the occasional spike thrown in for good measure sometimes i feel people can,t see the good for all the rubbish we all endure from all the rubbishy companies out there , one good contract and these go mental , of course aimho dyor etc etc .

[lady gaga] 07/6/2011 11:22

nice 750000 buy we may get going yet today

[lady gaga] 06/6/2011 09:39

It could do thay b 4 tea time. lol

The last move with this baby was a few months ago just out of the blue it moved up 227% in a few mins.

So get ready for a verry interesting few months here.

DYOR

But this one is a verry good bet,

As any sar val pyc summ news will have profit takers there move to the next cheap pharma.

And she will rly motor.

And were on the verge of profit next year.
Without that help

[lady gaga] 06/6/2011 09:32

All ready for the next step up.

[inv] 06/6/2011 09:31

Will move rapidly over the next 2 weeks to 0.6p plus

[lady gaga] 06/6/2011 09:20

This one has been over sold.

People looking for sub .2p to buy have been burned again.

We will see them buy in again in a rush above .3p.

Mark my words.

GLTA

LG

[andrbea] 06/6/2011 09:13

go on my son!

[lady gaga] 06/6/2011 08:56

Thanks mister 1million buyer.

Uve just ticked us up 5% more lol

Nice one.

Wheres the doc with his deramping words of NO wisdom.